Sarepta Therapeutics Inc (SRPT)

29.93
0.25 0.84
NASDAQ : Health Care
Prev Close 29.68
Open 29.72
Day Low/High 29.54 / 30.17
52 Wk Low/High 8.00 / 41.97
Volume 856.15K
Avg Volume 2.61M
Exchange NASDAQ
Shares Outstanding 54.81M
Market Cap 1.65B
EPS -5.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Shark Bites: Market Needs a Bounce in Its Step

Shark Bites: Market Needs a Bounce in Its Step

Biotechnology continues to be a bright spot.

Watching Financials and Biotech in This Tepid Market

Watching Financials and Biotech in This Tepid Market

Keep an eye on the pattern of morning weakness and afternoon strength.

Market Action Is Boring but Necessary

Market Action Is Boring but Necessary

After yesterday's surprise pullback, this is the sort of consolidation we need.

Market Taking a Break, but Probably Not for Long

Market Taking a Break, but Probably Not for Long

Today is more about stock picking.

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Aurinia Pharmaceuticals, Puma Biotechnology, PTC Therapeutics and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Notable Wednesday Option Activity: SRPT, PTCT, CBI

Notable Wednesday Option Activity: SRPT, PTCT, CBI

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sarepta Therapeutics Inc , where a total of 14,285 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 60.3% of SRPT's average daily trading volume over the past month of 2.4 million shares.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on February 28, 2017, that were previously approved by the Compensation Committee of...

Sarepta Therapeutics Announces Fourth Quarter And Full-Year 2016 Financial Results And Recent Corporate Developments

Sarepta Therapeutics Announces Fourth Quarter And Full-Year 2016 Financial Results And Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today...

5 Stocks Set for Explosive Breakouts

5 Stocks Set for Explosive Breakouts

Here's how to rake in the profits off some potential big breakouts.

More Selling Pressure, But No Rush for the Exits

More Selling Pressure, But No Rush for the Exits

If you play strong defense, be prepared to change course very quickly.

The Contrary Indicators Are Piling Up

The Contrary Indicators Are Piling Up

But it is all about timing, and so far there is no indication that this extended market is about to turn.

Some Stock Picks on This Morning's Dip

Some Stock Picks on This Morning's Dip

It will be interesting to see today if afternoon strength occurs once again.

Sarepta Leads Biotech Movers on Voucher Deal News

Sarepta Leads Biotech Movers on Voucher Deal News

Gilead (finally!) has acquired something from Sarepta, even if it is quite small.

Sarepta Therapeutics Agrees To Sale Of Priority Review Voucher For $125M

Sarepta Therapeutics Agrees To Sale Of Priority Review Voucher For $125M

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today announced it has entered into an agreement to sell its Rare Pediatric Disease Priority Review...

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Sarepta Therapeutics To Announce Fourth Quarter And Full-Year 2016 Financial Results And Recent Corporate Developments On February 28, 2017

Sarepta Therapeutics To Announce Fourth Quarter And Full-Year 2016 Financial Results And Recent Corporate Developments On February 28, 2017

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, will report fourth quarter and full-year 2016 financial results after the NASDAQ Global Market closes on Tuesday,...

Is Sarepta Actually Competing with Marathon?

Is Sarepta Actually Competing with Marathon?

TheStreet's Adam Feuerstein defends Sarepta Therapeutics

The Fed's Dilemma Is Quite Obvious

The Fed's Dilemma Is Quite Obvious

The Fed cannot move interest rates until fiscal policy is clear.

Defending Sarepta Against Blowback From the Marathon Pharma Steroid Price Gouging Scandal

Defending Sarepta Against Blowback From the Marathon Pharma Steroid Price Gouging Scandal

Sarepta and Marathon are not competing for the treatment of patients with Duchenne muscular dystrophy.

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on January 31, 2017, that were previously approved by the Compensation Committee of...

Trading Action Has Improved, Here's What I Am Playing

Trading Action Has Improved, Here's What I Am Playing

Market players are sorting out the winners and losers, and that produces good opportunities if we keep on digging.

Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix

Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix

TheStreet's Adam Feuerstein answers readers' questions about biotech stocks.

Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns

Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns

These companies show signs of a change of direction.

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)

Jim Cramer highlights bank, health-care companies reporting next week and what to watch.

Surge From Bank Earnings Doesn't Last

Surge From Bank Earnings Doesn't Last

Earnings and inauguration may be catalysts for the market.

7 Stocks Making Big Moves With Unusual Volume

7 Stocks Making Big Moves With Unusual Volume

Here's a technical look at how to trade stocks rising with unusual volume flow.